Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia

血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证

• 批准号: 10117295
• 负责人: Ian Alexander Blair
• 金额: $ 75.4万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-15 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10117295
• 关键词: Address; Affect; Age; Alleles; Alternative Splicing; Amino Acids; Biological; Biological Assay; Biological Markers; Blood; Blood Cells; Blood Platelets; Blood specimen; Cardiac; Cell Nucleus; Cessation of life; Clinical; Collection; Cultured Cells; Cytosol; Development; Disease; E protein; Erythrocytes; Friedreich Ataxia; Genes; Half-Life; High Pressure Liquid Chromatography; Immunoassay; Lateral; Length; Life; Mass Spectrum Analysis; Measurement; Methionine; Methods; Mitochondria; Mitochondrial Proteins; Monitor; Mutation; N-terminal; Pathology; Patients; Peptides; Plasma; Protein Isoforms; Proteins; Reaction; Resolution; Sampling; Sensitivity and Specificity; Serum; Site; Source; Specificity; Testing; Therapeutic Intervention; Therapeutic Trials; Time; Treatment Efficacy; Triplet Multiple Birth; Up-Regulation; Validation; Whole Blood; base; frataxin; healthy volunteer; liquid chromatography mass spectrometry; mitochondrial processing peptidase; nano; novel; novel therapeutic intervention; sample collection; stable isotope; therapy design; two-dimensional

ABSTRACT: ANALYTICAL VALIDATION OF FRATAXIN PROTEOFORMS IN BLOOD AS BIOMARKERS OF FRIEDREICH’S ATAXIA Friedreich’s ataxia (FA) is an autosomal recessive disease caused by an intronic GAA triplet expansion in the FXN gene, leading to reduced expression of the mitochondrial protein frataxin. FA is estimated to affect 1 in 50,000 with a mean age of death in the fourth decade of life. There are no approved treatments for FA, although experimental approaches, which involve up-regulation or replacement of frataxin protein, are being tested. Frataxin is undetectable in serum or plasma, and whole blood could not be used because frataxin was thought to be present in long-lived erythrocytes. An assay for analyzing frataxin in platelets, which have a half- life of 10 days, which would allow therapeutic interventions to be tested, was developed by the Blair and Lynch labs. The assay is based on stable isotope dilution immunopurification two-dimensional nano-ultra high performance liquid chromatography/parallel reaction monitoring/high resolution mass spectrometry (nano- UPLC-MS/HRMS) and is monitoring three tryptic peptides from frataxin. The assay had 100 % sensitivity and specificity for discriminating between controls and FA cases but analyzing platelets on a routine basis is very challenging in many clinical settings. We have now discovered that in erythrocyte is in fact a novel proteoform of frataxin (isoform E) with 135-amino acids (76-210) and an N-terminally acetylated methionine residue. It arises through an alternative splice-site form that is used for the canonical full-length form of frataxin (1-210). There is three times as much isoform E in erythrocytes (26.7 ± 6.4 ng/mL) from the blood of healthy volunteers (n=10) when compared with the mature mitochondrial frataxin present in other blood cells (7.1 ± 1.0 ng/mL). We recently found that both isoform E (8.5 ± 1.1 ng/mL) and mature mitochondrial frataxin (2.1 ± 1.1 ng/mL) are both reduced by > 70 % in blood from FA patients (n=29) when compared with healthy control subjects. Isoform E lacks a mitochondrial targeting sequence and so it is distributed to both cytosol and the nucleus when expressed in cultured cells. The ability to specifically quantify extra-mitochondrial and mitochondrial isoforms of frataxin in whole blood would make it possible to follow the progress of the disease and monitor the efficacy of therapeutic interventions. This will require the development of rigorously validated assays that address the pre-analytical and analytical issues that are relevant to the use of blood as a biological matrix for biomarker analysis rather than the more common use of serum or plasma. The present proposal addresses these issues under following specific aims: Aim 1: To conduct pre-analytical validation for collection and storage of mature frataxin and isoform E protein in whole blood. Aim 2: To conduct analytical validation of the method for quantifying mature mitochondrial frataxin and frataxin isoform E in whole blood. Aim 3: Validation of the mature frataxin and frataxin isoform E proteoform analysis in whole blood from controls, FA carriers, and FA cases from multiple sites.

摘要：血液中卵黄蛋白蛋白形态作为生物标志物的分析验证